Recent Patents on Bacterial Proteins as Potential Anticancer Agents

Fialho, Arsénio M.; Chakrabarty, Ananda M.

doi:10.2174/157489207782497163

Cited by 11 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the cupredoxin azurin has recently been shown to more preferentially enter cancer than normal cells and form a complex with the tumor suppressor protein p53, stabilizing it and increasing its intracellular level, thereby inducing apoptosis via caspase-mediated mitochondrial pathways or cell cycle arrest at G1 phase, depending on cell types …”

Section: Introductionmentioning

confidence: 99%

Advances in Copper Complexes as Anticancer Agents

et al. 2013

View full text Add to dashboard Cite

Copper is a transition metal that can exist in oxidized (Cu(II)) and reduced (Cu(I)) states. This allows it to participate in redox and catalytic chemistry, making it a suitable cofactor for a diverse range of enzymes and molecules. Copper complexes have been investigated for their therapeutic or diagnostic potential showing effectiveness in cancer treatment due to their cytotoxic action on tumour cells. In this review, the most remarkable achievements in the design and development of copper(I, II) complexes as antitumor agents are discussed. Special emphasis has been focused on the identification of structure-activity relationships for the different classes of complexes. Up to now, despite the enormous efforts in synthesizing different classes of copper complexes, very few data concerning the molecular basis of the mechanisms underlying their antitumor activity are available. The current overview, collecting the most significant strategies adopted in the last four years to design promising anticancer copper(I,II) compounds, aims to provide a useful reference for researchers working in this field

show abstract

Section: Introductionmentioning

confidence: 99%

Advances in Copper Complexes as Anticancer Agents

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In fact, in the recent past, many live or attenuated bacteria were patented as potential anticancer agents111213. Additionally, microbial products including toxins, enzymes, antibiotics, various proteins, peptides and other low molecular weight products have also been evaluated for their anticancer properties1214.…”

mentioning

confidence: 99%

Anticancer properties of a defensin like class IId bacteriocin Laterosporulin10

Baindara

Gautam

Raghava

et al. 2017

Sci Rep

107

View full text Add to dashboard Cite

Laterosporulin10 (LS10) is a defensin like peptide from Brevibacillus sp. strain SKDU10 that inhibited microbial pathogens. However, in this study, anticancer activity of LS10 was examined against different cancer cell lines and compared with normal cells. LS10 displayed cytotoxicity against cancer cells like MCF-7, HEK293T, HT1080, HeLa and H1299 at below 10 μM concentration, but not against prostate epithelium cells RWPE-1. Additionally, no hemolysis was observed at significantly higher concentration compared to IC50 values observed for different cancer cell lines. Release of lactate dehydrogenase from cancer cell lines at 15 μM concentration upon 120 min treatment indicated the lytic ability of LS10. Accordingly, electron microscopy experiments also confirmed the necrotic effect of LS10 at 15 μM concentration against cancer cells. Furthermore, flow cytometry analysis of treated cancer cell lines revealed that LS10 induce apoptosis even at 2.5 μM concentration. Nevertheless, RWPE-1 cells remained viable even at 20 μM concentration. These results provide evidence that LS10 is an anticancer bacteriocin, which causes apoptotic and necrotic death of cancer cells at lower and higher concentrations, respectively. Taken all results together, the present study signifies that LS10 is an anticancer peptide that could be further developed for therapeutic applications.

show abstract

“…Similarly, other well-known bacterial molecules, such as MPT63 ( M. bovis ), arginine deiminase ( Mycoplasma arginine ), lapidated-azurin ( Neisseria meningitidis ), and azurin ( P. aeruginosa ), have been reported as potential anticancer drugs ( 29 ). However, factors such as bacterial endotoxin, manufacturing technique, protein stability, administration mode, and biosafety still need to be addressed when utilizing bacteria-derived proteins as antitumoral drugs ( 29 , 30 ).…”

Section: Discussionmentioning

confidence: 99%

Pseudomonas aeruginosa PcrV Enhances the Nitric Oxide-Mediated Tumoricidal Activity of Tumor-Associated Macrophages via a TLR4/PI3K/AKT/mTOR-Glycolysis-Nitric Oxide Circuit

Bai

Qiu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs), which display a tumor-supportive M2 phenotype, are closely related to tumor growth and metastasis. The reprogramming of TAMs toward a tumoricidal M1 profile has emerged as an attractive strategy for cancer immunotherapy. In this study, we found that the intratumoral injection of PcrV protein, a component of the Pseudomonas aeruginosa type 3 secretion system, suppressed tumor growth and increased apoptosis, inducible nitric oxide synthase (iNOS) expression, and the percentage of M1-polarized TAMs in tumor tissues. Furthermore, the intratumoral injection of PcrV-primed macrophages exerted a similar tumoricidal effect. In vitro analyses revealed that PcrV reeducated TAMs toward an antitumoral M1 phenotype and augmented their nitric oxide (NO)-mediated cytotoxicity against cancer cells. Mechanistically, we found that these effects were dependent on the activation of Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)-mediated regulation of a PI3K/AKT/mTOR-glycolysis-NO feedback loop via direct interaction with TLR4. Collectively, these results revealed a potential role for PcrV in cancer immunotherapy through the targeting of TAM plasticity.

show abstract

Recent Patents on Bacterial Proteins as Potential Anticancer Agents

Cited by 11 publications

References 50 publications

Advances in Copper Complexes as Anticancer Agents

Advances in Copper Complexes as Anticancer Agents

Anticancer properties of a defensin like class IId bacteriocin Laterosporulin10

Pseudomonas aeruginosa PcrV Enhances the Nitric Oxide-Mediated Tumoricidal Activity of Tumor-Associated Macrophages via a TLR4/PI3K/AKT/mTOR-Glycolysis-Nitric Oxide Circuit

Contact Info

Product

Resources

About